- Supported exchanges /
- ST /
- DMYD-B.ST
Diamyd Medical AB (publ) (DMYD-B ST) stock market data APIs
Diamyd Medical AB (publ) develops precision medicine therapies for the treatment of autoimmune diabetes. The company develops Diamyd, an antigen-specific immunotherapy, which is in phase III clinical trial for the treatment of type 1 diabetes and latent autoimmune diabetes in adults (LADA); and Remygen, an immunomodulation therapy, that is in phase I/II clinical trial for the treatment of with type 1 diabetes, type 2 diabetes, and LADA. It has a research and development collaboration agreement with Juvenile Diabetes Research Foundation to develop DIAGNODE-3 Phase 3 trial in type 1 diabetes. The company was formerly known as Diamyd Therapeutics AB and changed its name to Diamyd Medical AB (publ) in April 2013. Diamyd Medical AB (publ) was founded in 1984 and is headquartered in Stockholm, Sweden.
Diamyd Medical AB (publ) Financial Data Overview
| 12.72 | |
| 12.61 | |
| - | |
| 12.89 | |
| 12.15 | |
| 6.41-25 | |
| 1 322 M | |
| 101 M | |
| 130 K | |
| -0.4988 | |
| 2.139 |
No long-term obligations. The minimum period is one month only. No wait. You get an API key with instructions in a few seconds right after subscription.
Diamyd Medical AB (publ) Fundamental Data is available in our Financial Data APIs
- Net Revenue 130 K
- EBITDA -141 694 000
- Earnings Per Share -1.6
- Income Statements
- Balance Sheets
- Cash flows
of Fundamental API Data
Get Diamyd Medical AB (publ) Earnings via APIs
- Latest Release 2024-08-31
- EPS/Forecast NaN
Get Diamyd Medical AB (publ) End-of-day Data via APIs
- End of Day, Intraday and Live APIs
- Splits
- Dividends
Our 24/7 support would be happy to assist you via chat or email:
support@eodhistoricaldata.comVisit also:
